Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer
Drug Resistance Updates · 2024-03 · 73 · 101051
DOI: 10.1016/j.drup.2024.101051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-03. Verfasst von Hailin Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, No. 628 Zhenyuan Road, Shenzhen 518107, Guangdong, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Science, Technology and Innovation Commission of Shenzhen Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Trastuzumab resistance in HER2+ breast cancer (BC) is the major reason leading to poor prognosis of BC patients. Oncogenic gene overexpression or aberrant activation of tyrosine kinase SRC is identified to be the key modulator of trastuzumab response. However, the detailed regulatory mechanisms underlying SRC activation-associated trastuzumab resistance remain poorly understood. In the present study, we discover that SRC-mediated YAP1 tyrosine phosphorylation facilitates its interaction with transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha, TFAP2A), which in turn promotes YAP1/TEAD-TFAP2A (YTT) complex-associated transcriptional outputs, thereby conferring trastuzumab resistance in HER2+ BC. Inhibition of SRC kinase activity or disruption of YTT complex sensitizes cells to trastuzumab treatment in vitro and in vivo. Additionally, we also identify YTT complex co-occupies the regulatory regions of a series of genes related to trastuzumab resistance and directly regulates their transcriptions, including EGFR, HER2, H19 and CTGF. Moreover, YTT-mediated transcriptional regulation is coordinated by SRC kinase activity. Taken together, our study reveals that SRC-mediated YTT complex formation and transcriptions are responsible for multiple mechanisms associated with trastuzumab resistance. Therefore, targeting HER2 signaling in combination with the inhibition of YTT-associated transcriptional outputs could serve as the treatment strategy to overcome trastuzumab resistance caused by SRC activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, No. 628 Zhenyuan Road, Shenzhen 518107, Guangdong, China.
- Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-sen University, No. 628 Zhenyuan Road, Shenzhen 518107, Guangdong, China.
- Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, No. 628 Zhenyuan Road, Shenzhen 518107, Guangdong, China; Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seve…
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Science, Technology and Innovation Commission of Shenzhen Municipality
- National Natural Science Foundation of China
Zitieren
APA
Zou, H., Luo, J., Guo, Y., Deng, L., Zeng, L., Pan, Y., & Li, P. (2024). Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer. Drug Resistance Updates, 73, 101051. https://doi.org/10.1016/j.drup.2024.101051
Vancouver
Zou H, Luo J, Guo Y, Deng L, Zeng L, Pan Y, et al. Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer. Drug Resistance Updates. 2024;73:101051. doi:10.1016/j.drup.2024.101051
BibTeX
@article{Zou2024,
author = {Zou, Hailin and Luo, Juan and Guo, Yibo and Deng, Liang and Zeng, Leli and Pan, Yihang and Li, Peng},
title = {Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer},
journal = {Drug Resistance Updates},
year = {2024},
volume = {73},
pages = {101051},
doi = {10.1016/j.drup.2024.101051}
}
EUVIMED